MP CARDIOFLOW-B (02160) saw its shares surge more than 9% during the trading session. At the time of writing, the stock was up 6.06%, trading at HK$1.05, with a turnover of HK$4.4837 million. The catalyst for the movement is the approval for market launch in Morocco of MP CARDIOFLOW's VitaFlow Liberty transcatheter aortic valve and retrievable delivery system. This approval marks the product's inaugural entry into the African market. The Moroccan medical device market exhibits a high dependency on imported products, and this approval lays a solid foundation for the subsequent expansion of the product into other African nations.

Notably, on December 19, MicroPort Scientific announced the completion of the merger involving MP CARDIOFLOW's acquisition of a cardiac rhythm management business. This merger is set to drive the deep integration of MicroPort Scientific's two core business segments: structural heart disease and cardiac rhythm management. With the announcement of the latest integration plan, it signifies that MicroPort Scientific is accelerating its efforts to build a comprehensive device management solution that covers the full spectrum of causes, all stages, and the entire process of heart failure.